CDK2 and breast cancer: Since the Cyclin E/CDK2 activation has been reported as an important mechanism of CDK4/6 inhibitor resistance29, we hypothesized that MITH may be a biomarker for CDK4/6 inhibitor resistance in HR+ breast cancers.